A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Japan: Pharmaceuticals and Medical Devices Agency
CASA404A1102
NCT01285453
March 2009
Name | Location |
---|